Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Non Operating Income (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Non Operating Income for 5 consecutive years, with $256000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Income fell 55.56% to $256000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.4 million, a 38.26% decrease, with the full-year FY2024 number at $3.0 million, down 34.39% from a year prior.
  • Non Operating Income was $256000.0 for Q3 2025 at Lyra Therapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1.4 million in Q2 2025 to a low of $14000.0 in Q1 2022.
  • A 5-year average of $554684.2 and a median of $435000.0 in 2024 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: surged 7557.14% in 2023, then plummeted 72.56% in 2025.
  • Lyra Therapeutics' Non Operating Income stood at $21000.0 in 2021, then surged by 4342.86% to $933000.0 in 2022, then skyrocketed by 43.41% to $1.3 million in 2023, then crashed by 67.49% to $435000.0 in 2024, then crashed by 41.15% to $256000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Non Operating Income are $256000.0 (Q3 2025), $1.4 million (Q2 2025), and $298000.0 (Q1 2025).